Denis is Vice President, WRDM, Head of Partnering Innovation, and Managing Partner of Pfizer Ventures. Denis capitalizes upon his experience in evaluating external opportunities to identify and manage equity investments. He currently has responsibility for Pfizer’s investments in AnTolRx, Aquinnah Pharmaceuticals, EvolveImmune Therapeutics, FoRx Therapeutics, Metabomed, MISSION Therapeutics and Palleon Pharma. His prior investment responsibilities include Bolt Biotherapeutics (BOLT), eFFECTOR Therapeutics (EFTR), and NextCure (NXTC). Previously, Denis served as Head of Oncology Licensing for Worldwide R&D at Pfizer from 2010 to 2018. Previously, Denis worked for Merck, DuPont Pharma, and GSK. He contributed to the approval of three marketed therapeutic agents including nelarabine, trametinib, and dabrafenib. Denis received his PhD in Biochemistry from the University of Pennsylvania.
- Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
- Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
- Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023